HCW Biologics Inc.
HCWBAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | maintain | Buy | May 28, 2026 |
| Maxim Group | maintain | Buy | May 29, 2025 |
| EF Hutton | maintain | Buy | Apr 19, 2023 |
| EF Hutton | maintain | Buy | Mar 30, 2023 |
| EF Hutton | maintain | Buy | Mar 23, 2023 |
| JonesTrading | maintain | Buy | Nov 8, 2022 |
| Maxim Group | maintain | Buy | Mar 24, 2022 |
| EF Hutton | maintain | Buy | Nov 19, 2021 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-1.35| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-11.58 | $-1.98 | $135.6K | $135.6K |
| May 14, 2026 | $2.22 | $-2.64 | $6.5M | $6.5M |
| Mar 31, 2026 | $-15.78 | $-5.04 | $27.0K | $7.0M |
| Nov 14, 2025 | $-12.12 | $9.48 | $85.3K | $7.0M |
| Aug 18, 2025 | $-40.73 | $10.80 | $1.3K | $7.0M |
| May 15, 2025 | $-0.30 | — | $5.1K | — |
| Mar 28, 2025 | $-19.20 | $21.60 | $394.8K | $7.0M |
| Nov 14, 2024 | $-24.00 | $-31.20 | $852.9K | — |
News
Designated as one of the Top 150 abstracts submitted for the 41 st Annual Meeting of the Society for Immunotherapy of Cancer
HCW11-018b induces/promotes tertiary lymphoid structure formation inside tumors HCW11-018b converts immunological “cold” tumors into “hot” tumors HCW11-018b was generated using the Company's non-Fc TRBC platform, combining elements that enhance T-cell activation and tumor infiltration while mitigating immunosuppression MIRAMAR, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company and…
Provides funding needed to complete HCW9302 Phase 1 study in alopecia areata and establish Recommended Phase 2 Dose Provides funding needed to complete HCW9302 Phase 1 study in alopecia areata and establish Recommended Phase 2 Dose
HCW Biologics Inc. (NASDAQ: HCWB - Get Free Report) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 60,941 shares, an increase of 557.1% from the September 15th total of 9,274 shares. Based on an average daily trading volume, of 1,348,961
Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer
MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.5 million private placement (the “Offering”) with an existing stockholder of the Company, (the “Investor”).
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent
HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatment for alopecia areata Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata on track for completion in Q4 2026, continues to be well tolerated with no dose-limiting toxicities Preliminary readout of first two dose cohorts is encouraging -- patient…
Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8 + T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel…
MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and six months ended June 30, 2026.